Malignancies
Drug research and approvals for malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 18,858 studies of malignancies are recruiting on ClinicalTrials.gov, Health Canada has authorized 91 drug trials for it since 2013, FDA has 5 approved and 11 open orphan designations naming it, and the EU has 23 authorised medicines for it.
- Recruiting worldwide: 18,858
- Trials authorized in Canada: 91
- FDA orphan approvals: 5
- EU medicines: 23
Recruiting Now
Newest start dates first, of 18,858 recruiting on ClinicalTrials.gov ↗- Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and…NCT06485908 · Phase 1 / Phase 2 · Assistance Publique Hopitaux De Marseille · starts Feb 1, 2032
- Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a…NCT07202507 · Not applicable · Centre Oscar Lambret · starts Sep 1, 2027
- Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsNCT07170293 · Phase 2 · Tianjin Medical University Second Hospital · starts Aug 31, 2027
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP…NCT07649304 · Phase 1 · National Cancer Institute (NCI) · starts Jul 5, 2027
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to…NCT07437963 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jun 25, 2027
- Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging…NCT04861077 · Early Phase 1 · University of Alabama at Birmingham · starts Jun 1, 2027
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced…NCT07619521 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jun 1, 2027
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard…NCT07551596 · Phase 2 · National Cancer Institute (NCI) · starts May 25, 2027
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment…NCT06948084 · Phase 2 · National Cancer Institute (NCI) · starts May 22, 2027
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell…NCT07516366 · Phase 2 · National Cancer Institute (NCI) · starts May 17, 2027
Trials Authorized in Canada
The 10 newest of 91; search them all in Canada trials| Nov 13, 2026 | Dualis: a modular phase I/ii, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and…AZD1221 | AstraZeneca Pharmaceuticals LP | Pending |
| Sep 4, 2026 | Baf_frontier-1, a first-in-human, phase 1 trial to assess safety, tolerability, and preliminary efficacy of ly4152199, a b-cell activation factor receptor…LY4152199 | Eli Lilly | Pending |
| Jul 15, 2026 | A phase 3, prospective, open-label, multicenter, single-arm study to investigate the efficacy, safety, and pharmacokinetics of igpro20 in subjects with…HIZENTRA | CSL | Pending |
| Apr 23, 2026 | An open-label phase 1 study to evaluate pf-07994525 in participants with advanced malignanciesPF-07994525 | Pfizer | Ongoing |
| Oct 24, 2025 | A phase 1b / 2, multicenter, multi arm study of evorpacept in combination with anti-cancer therapies in advanced / metastatic malignancies / a single-arm phase…EVORPACEPT (ALX148) /TRASTUZUMAB / TARO-CAPECITABINE / HALAVEN (ERIBULIN) /… | ALX ONCOLOGY INC. | Ongoing |
| Oct 8, 2025 | An open-label phase 1 study to evaluate pf-08046037 as monotherapy and part of combination therapy in participants with advanced malignanciesPF-08046037 / SASANLIMAB (PF-06801591) | Pfizer | Closed |
| Sep 11, 2025 | Help-study - towards high throughput and efficient long-axial pet with oral [18f]fdgFLUDEOXYGLUCOSE (18F) | BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY - VANCOUVER CENTER | Ongoing |
| Sep 10, 2025 | Study of azd3632 monotherapy or in combination with anticancer agents in participants with advanced haematologic malignancies with kmt2ar, npm1m, or other…AZD3632 | AstraZeneca Pharmaceuticals LP | Pending |
| Oct 25, 2024 | A phase 1/1b first-in-human trial of bms-986484 as monotherapy and combination therapy in participants with advanced solid malignanciesBMS-986484 / OPDIVO | Bristol-Myers Squibb | Ongoing |
| Aug 15, 2024 | Lightbeam-u01 substudy 01a: a phase 1/2 substudy to evaluate the safety and efficacy of zilovertamab vedotin in pediatric and young adult participants with…ZILOVERTAMAB VEDOTIN (MK-2140) / PATRITUMAB DERUXTECAN / IFINATAMAB DERUXTECAN | Merck & Co. (MSD) | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 16| Apr 17, 2023 | Omisirgefor use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood… | Gamida Cell Ltd. | Approved |
| Jul 12, 2002 | ElitekInitial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving… | Sanofi-Synthelabo Research | Approved |
| Feb 4, 1999 | BusulfexFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation… | Otsuka Pharmaceutical Company, Ltd | Approved |
| May 17, 1996 | Aloprim for InjectionManagement of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of… | Catalytica Pharmaceuticals, Inc | Approved |
| Jun 15, 1994 | NeupogenReduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy… | Amgen, Inc. | Approved |
| Nov 14, 2023 | mocravimodTreatment to improve outcome following hematopoietic stem cell transplantation in hematologic malignancies | Priothera SAS | Designated |
| Jun 24, 2013 | liposomal busulfanFor use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation | Calliditas Therapeutics AB | Designated |
| Apr 6, 2012 | ferumoxytolFor use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric… | ArsNova Partners, LLC | Designated |
| Sep 12, 2008 | Human Allogeneic HLA-matched, Umbilical Cord Blood…Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with… | Mesoblast, Inc. | Designated |
| Apr 27, 2007 | Attenuated autologous cancer cells and granulocyte…Treatment of primary central nervous system malignancies | TVAX Biomedical, LLC | Designated |
| Jul 3, 2000 | CarmustineTreatment of intracranial malignancies. | Direct Therapeutics, Inc. | Designated |
| Feb 27, 1998 | ThalidomideTreatment of primary brain malignancies. | Celgene Corporation | Designated |
| Jul 7, 1997 | BusulfanTreatment of primary brain malignancies. | SuperGen, Inc. | Designated |
| Apr 21, 1994 | BusulfanFor use as preparative therapy for malignancies treated with bone marrow transplantation. | Sparta Pharmaceuticals, Inc. | Designated |
| Sep 7, 1988 | Serratia marcescens extract (polyribosomes)Treatment of primary brain malignancies. | Cell Technology, Inc. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 23| Aug 28, 2026 | Denosumab Ascenddenosumab · biosimilar | Ascend GmbH | EMA ↗ |
| Nov 17, 2025 | Degevmadenosumab · biosimilar | Teva GmbH | EMA ↗ |
| Nov 17, 2025 | Xbonzydenosumab · biosimilar | Reddy Holding GmbH | EMA ↗ |
| Nov 17, 2025 | Zvogradenosumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Sep 17, 2025 | Bilprevdadenosumab · biosimilar | Sciencepharma Sp. z o.o | EMA ↗ |
| Aug 25, 2025 | Zemcelproallogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel · orphan | Cordex Biologics International Limited | EMA ↗ |
| Jul 17, 2025 | Bomyntradenosumab · biosimilar | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Jun 26, 2025 | Denbraycedenosumab · biosimilar | Mabxience Research SL | EMA ↗ |
| Jun 26, 2025 | Enwylmadenosumab · biosimilar | Zentiva k.s. | EMA ↗ |
| Jun 25, 2025 | Vevzuodenosumab · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Jun 23, 2025 | Yaxwerdenosumab · biosimilar | Gedeon Richter Plc. | EMA ↗ |
| May 26, 2025 | Jubereqdenosumab · biosimilar | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 14, 2025 | Osenveltdenosumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Feb 12, 2025 | Xbrykdenosumab · biosimilar | Samsung Bioepis NL B.V. | EMA ↗ |
| May 17, 2024 | Wyostdenosumab · biosimilar | Sandoz GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA